A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease

NCT07246941 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Huntington's Disease

Interventions

DRUG: RG6496
DRUG: Placebo

Sponsor

Hoffmann-La Roche